



Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	E
Search	PubMed	▼ for Swanson S and detection					Preview	Go	
		✓ Limits	Preview/Index	History	Clipboard	Details			

- Search History will be lost after eight hours of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.

Entrez
PubMed

Search	Most Recent Queries	Time	Result
#49	Search Swanson S and detection Limits: Publication Date to 1999/08/25	14:33:18	<u>23</u>
#48	Search Swanson S and adenovirus Limits: Publication Date to 1999/08/25	14:32:39	<u>1</u>
#47	Search Swanson S Limits: Publication Date to 1999/08/25	14:32:29	<u>326</u>
#46	Search Mytych D Limits: Publication Date to 1999/08/25	14:32:08	<u>2</u>
#45	Search peptide linker and CKGKG Limits: Publication Date to 1999/08/25	14:26:12	<u>1195</u>
#44	Search peptide linker Limits: Publication Date to 1999/08/25	14:25:57	<u>1195</u>
#43	Search CKGKG Field: All Fields, Limits: Publication Date to 1999/08/25	14:25:36	<u>0</u>
#36	Search Lemon S and HCV Limits: Publication Date to 2000/12/23	09:59:45	<u>22</u>
#35	Search Lemon S Limits: Publication Date to 2000/12/23	09:46:17	<u>174</u>
#34	Search HCV replicon and tat Limits: Publication Date to 2000/12/23	09:43:39	<u>0</u>
#30	Search transactivation and HCV Field: All Fields, Limits: Publication Date to 2000/12/23	09:40:14	<u>13</u>
#28	Search Guo 2001 and HCV	09:14:26	<u>5</u>
#27	Search Guo 2000 and HCV	09:14:08	<u>4</u>
#25	Search Blight 2000 and hcv	09:08:04	<u>2</u>
#23	Search Bartenschlager 2000 and hcv	09:00:41	<u>4</u>
#20	Search Lohmann 1999 and HCV	08:46:00	<u>6</u>
#18	Search Lohmann 2001 and HCV	08:42:26	<u>7</u>
#16	Search Pietschamnn 2001 and self-replication Field: All Fields, Limits: Publication Date to 2000/12/23	08:40:04	<u>12</u>
#15	Search Pietschamnn 2001 and self-replication	08:39:23	<u>27</u>
#14	Search Pietschamnn 2001 and HCV RNA	08:39:12	<u>1059</u>
#13	Search Pietschamnn 2001 and HCV	08:38:37	<u>2577</u>
#11	Search Reynolds 1995 and HCV	08:37:24	<u>2</u>
#9	Search Reynolds 1996 and HCV	08:36:45	<u>1</u>

PubMed
Services

Related
Resources

```

=> "peptide linker"
    305983 "PEPTIDE"
    223298 "PEPTIDES"
    391308 "PEPTIDE"
        ("PEPTIDE" OR "PEPTIDES")
    14823 "LINKER"
    3477 "LINKERS"
    16810 "LINKER"
        ("LINKER" OR "LINKERS")
L5      359 "PEPTIDE LINKER"
        ("PEPTIDE" (W) "LINKER")

=> antigen and L1
    249705 ANTIGEN
    198079 ANTIGENS
    309817 ANTIGEN
        (ANTIGEN OR ANTIGENS)
L6      87 ANTIGEN AND L1

=> assay and L6
    300651 ASSAY
    128138 ASSAYS
    392648 ASSAY
        (ASSAY OR ASSAYS)
L7      4 ASSAY AND L6

=> adenovirus and L6
    19990 ADENOVIRUS
    2838 ADENOVIRUSES
    20494 ADENOVIRUS
        (ADENOVIRUS OR ADENOVIRUSES)
L8      0 ADENOVIRUS AND L6

```

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:238402 CAPLUS
DOCUMENT NUMBER: 126:220707
TITLE: Multimer compositions for conferring immunogenicity to a peptide
INVENTOR(S): Stanton, G. John; Hughes, Thomas K., Jr.; Smith, Eric M.
PATENT ASSIGNEE(S): Board of Regents, the University of Texas System, USA
SOURCE: PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9705886	A1	19970220	WO 1996-US12632	19960805
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5807552	A	19980915	US 1995-511662	19950804
AU 9666452	A1	19970305	AU 1996-66452	19960805
PRIORITY APPLN. INFO.:			US 1995-511662	19950804
			WO 1996-US12632	19960805

ABSTRACT:
A multimer of monomers non-covalently held together by interactive *****peptide*** linkers** if provided for the enhancement of the immunogenicity of a substance. These multimers are useful for stimulating or suppressing the immune system, detecting the presence of antibodies, bypassing MHC restriction in an animal, and the effective presentation of **antigen**, suppressing autoimmune disease, inducing cytokine production, adsorption, treating a defective immune system and for use as an adjuvant. The invention specifically describes multimers in which monomers are peptide sequences containing an HIV HP-6 epitope with left- and right-flanking linker sequences.

L7 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1996:162202 CAPLUS
DOCUMENT NUMBER: 124:229436
TITLE: Production and characterization of bispecific single-chain antibody fragments
AUTHOR(S): De Jonge, Jan; Brissinck, Jan; Heirman, Carlo; Demanet, Christian; Leo, Oberdan; Moser, Muriel; Thielemans, Kris
CORPORATE SOURCE: Lab. Physiol., Med. Sch. Vrije Univ. Brussel, Brussels, B-1090, Belg.
SOURCE: Molecular Immunology (1995), 32(17/18), 1405-12
CODEN: MOIMD5; ISSN: 0161-5890
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
ABSTRACT:
We report the construction, expression and purification of a bispecific single-chain Fv antibody fragment produced in Escherichia coli. The protein possesses a dual specificity: the single-chain FvB1 portion is directed to the Idiotypic of BCL1 lymphoma cells, the single-chain Fv2C11 moiety binds to the CD3 marker on T cells. The two domains are joined by a flexible **peptide** *****linker*****. Using Immobilized Metal Affinity Chromatog., the recombinant protein was purified from bacterial insol. membrane fractions. After refolding of the bispecific protein, it was affinity-purified. As demonstrated by flow

cytometry, both binding sites are retained in the refolded protein. Retargeted cytotoxicity and T cell proliferation **assays** further prove the biol. activity and specificity of the bispecific single-chain Fv. Thus, these bispecific mols. show a potential antitumor activity.